Date lodged: 1 June 2018
To ask the Scottish Government, in the light of the US National comprehensive clinical updated guidelines on using F-18 fluviclovivine (Axumin) in diagnostic imaging in men with recurrent prostate cancer, whether it will recommend that clinicians should consider using Axumin in positronic emission tomography, computed tomography or magnetic resonance imaging in helping to determine the best treatment.
Answered by: Shona Robison 12 June 2018
In 2017, SHTG found limited evidence supporting the use of Axumin for the detection of a suspected recurrent prostate cancer. The evidence base will be reviewed again in 2019, if not sooner should substantial new evidence become available.